EventDr. Bilge Güvenç Tuna

Atherosclerotic plaque prevention by targeted and controlled delivery of transglutaminase inhibitor

Atherosclerosis, which adversely affects arteries is a widespread coronary artery disease. In normal cases, the arteries expand and accordingly adjusts the amount of blood flow speed through arteries. Due to various reasons, atherosclerosis plaques are formed by losing flexibility of the arterial wall. These plaques cause clotting of arteries and veins and can lead to the formation of various complications. At this stage of the disease, it is difficult to reduce plaque formation. Therefore, preventive measures to minimize formation of plaques is considered to be best therapy approach. Specific inhibition of plaque forming enzyme activity such as transglutamase can prevent atherosclerotic vascular inflammation by blocking monocyte infiltration through endothelial layers. Synthesizing a targeted and controlled transglutaminase inhibitor release system can be a viable translational application for the inorganic nano-containers loaded with inhibitors.

bilge-guvenc-tuna-abst

About The Speaker

Bilge-Guvenc-Tuna

Dr. Bilge Guvenc Tuna received her B.Sc. from Middle East Technical University Physics Department and M.Sc. from Hacettepe University, Department of Biophysics. Dr. Tuna obtained her Ph.D. degree from Academic Medical Center, Department of Biomedical Engineering and Physics, Amsterdam University in 2014. She has worked on vascular remodeling on the influences of various cardiovascular pathologies including hypertension, subarachnoid hemorrhage and flow restriction models. Currently she is working on developing aptamer drug conjugates and (nano)biosensors for health applications. She is an assistant professor in Yeditepe University Faculty of Medicine, Department of Biophysics.